longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

BOYA BIOLOGY

300294

14.100.71% ( +0.10 )
Delay Closed: Sep 17, 15:00:00
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • CR Boya Bio-pharmaceutical, China Resources Pharmaceutical subsidiary, posts 77.28% drop in H1 net profit attributable to shareholders to RMB 51.19 million

    PUBT·Aug 21 at 08:52 AM
    300294+0.71%
  • China Resources Pharma's subsidiary China Resources Boya Biology earned 113 million RMB for the year, a decline of 71.6%

    AASTOCKS·Mar 22 at 05:04 AM
    588860+0.47%03320+0.12%
  • China Resources Pharma's recombinant coagulation factor IX has received the clinical trial approval notice for drugs in mainland China

    AASTOCKS·Feb 25 at 04:29 AM
    588130+0.31%159892+1.94%
  • CHINARES PHARMA subsidiary BOYA BIOLOGY expects a significant decrease in annual net profit due to impairment reduction

    AASTOCKS·Feb 1 at 09:51 AM
    03320+0.12%300294+0.71%
  • China Resources Pharmaceutical's subsidiary BOYA BIOLOGY earned 343 million RMB in the first nine months, a decline of 16.8%

    AASTOCKS·Oct 27, 2025 at 02:16 PM
    300294+0.71%
  • BOYA BIOLOGY: Completed the transfer of 80% equity in Jiangxi Boya Xinhao Pharmaceutical Co., Ltd

    Zhitong·Sep 9, 2025 at 08:58 AM
    300294+0.71%
  • BOYA BIOLOGY released its performance for the first half of the year, with a net profit attributable to the parent company of 225 million yuan, a decrease of 28.68%

    Zhitong·Aug 22, 2025 at 08:41 AM
    300294+0.71%
  • BOYA BIOLOGY has established a single plasma collection company in Inner Mongolia

    Zhitong·Jun 27, 2025 at 02:13 AM
    300294+0.71%
  • CHINARES PHARMA's subsidiary BOYA BIOLOGY's blood plasma collection station has been issued a business license by the Market Supervision Administration of Dalat Qi

    AASTOCKS·Jun 26, 2025 at 08:31 AM
    03320+0.12%300294+0.71%
  • BOYA BIOLOGY plans to jointly invest with Chengdu Hengnashun to establish a company to enhance the supply capacity of raw plasma

    Zhitong·May 30, 2025 at 11:11 AM
    300294+0.71%
  • BOYA BIOLOGY: Approved for the supplemental application of intravenous immunoglobulin drug

    Zhitong·May 30, 2025 at 10:34 AM
    300294+0.71%
  • BOYA BIOLOGY: Human Immunoglobulin (pH4) has obtained the drug registration certificate from the Dominican Republic

    Zhitong·May 27, 2025 at 08:23 AM
    300294+0.71%
  • BOYA BIOLOGY appoints Vice President Ren Hui as President

    Zhitong·May 16, 2025 at 12:10 PM
    300294+0.71%